Quantori Strengthens Global Leadership Team, Names Senior Business Leader Solman Rahman as Executive Vice President, Europe
8.9.2021 07:00:00 EEST | Business Wire | Press release
Quantori, a leading global provider of end-to-end software engineering, scientific informatics, data sciences and digital transformation services for life science and healthcare companies, today announced the appointment of Solman Rahman to Executive Vice President, Europe to support Quantori’s aggressive growth strategy and strengthen its market position as a premier global services provider.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210907005840/en/
Solman Rahman, Executive Vice President, Europe, Quantori (Photo: Business Wire)
“Solman’s wealth of experience in building and scaling business operations for leading technology consulting and digital platform engineering companies serving the European life science and healthcare markets makes him uniquely positioned to lead Quantori’s expansion in this key region,” said Richard Golob, CEO, Quantori. “Europe continues to be a powerhouse of world-class life science and biopharma industry innovation. We look forward to working with Solman in developing strategic client relationships to help biopharma and life science companies deliver critical technology programs and data management imperatives to accelerate development of novel therapeutics."
As Quantori’s Executive Vice President for Europe, Solman will be responsible for developing key partnerships within the EU region’s ecosystem of pharma and healthcare companies, in addition to ensuring delivery of superior services and providing leading technology capabilities to Quantori’s clients. Solman joins Quantori from EPAM Systems where he led the Northern Europe business and where he previously worked with Quantori leadership, including Richard Golob, who led EPAM’s Global Life Sciences Business into the fastest growing unit at EPAM, in addition to Dr. Yuriy Gankin, Quantori’s Chief Scientific Officer, and Vitaliy Aronov, Quantori’s Chief Technology Officer.
“I am thrilled to be rejoining such a brilliant executive team at a very exciting time in Quantori’s growth and development, especially as the European biopharma industry is scaling the use of digital technologies to enable the provision of precision medicines and personalized healthcare,” said Solman. “A major challenge in working with IT outsourcing companies is that they have a limited understanding of the life sciences and healthcare industries. One of Quantori’s key differentiators is its extensive domain knowledge underpinned by true scientific depth. This unique combination enables us to add considerable value from the outset and speed-to-market horsepower to the critical focus of today’s biopharma companies – to accelerate the translation of their research and data insights into a pipeline of new medicines.”
Prior to leading EPAM’s Northern European business, Solman worked at Cognizant in several roles, including serving as Head of Strategic Engagements and Industry Practice leadership. Solman began his career as an analyst at Cowen Inc. in the Technology Investment Banking Group, undertaking equity research in the biopharma and high-tech sectors. He currently serves as a board advisor to Conversationly, a digital agency leveraging messaging, automation and AI technologies to promote conversational commerce. He holds MSc and BSc degrees in Economics & Management and Econometrics from the London School of Economics and Political Science.
“We are thrilled to welcome Solman onboard, and he will be instrumental in our efforts to expand operations in Europe to help biopharma leaders bring novel and life-saving therapies to market through the powerful partnership of digital IT and R&D informatics,” said Yuriy Gankin, PhD, Quantori’s Chief Scientific and Strategy Officer.
About Quantori
Quantori is transforming life sciences and healthcare through the power of digital IT. Quantori develops end-to-end software engineering, scientific informatics, and data science solutions that help biopharma companies accelerate every stage of drug discovery and development. Quantori combines data engineering and advanced analytics with deep scientific domain knowledge to enable life science and healthcare organizations to achieve their digital transformations with greater speed and agility. Learn more about Quantori at www.quantori.com and connect on social media @Twitter, @LinkedIn, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005840/en/
Contact information
Heidi Creighton
heidi.creighton@quantori.com
Mobile/Text: 978-302-1198
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release
TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom